Aiming to interrupt the escape from immune surveillance, immunotherapeutic agents that target immune checkpoints including PD-L1/PD-1 and CTLA-4 have exhibited promising survival benefits in patients with metastatic melanoma, non-small cell lung cancer, and metastatic renal cancer in recent years (52–54). This evidence concerns the gene CTLA4 and metastatic melanoma.